| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF AMIVANTAMAB IN ADDITION TO CARBOPLATIN AND PEMBROLIZUMAB, COMPARED TO STANDARD OF CARE PLATINUM AND PEMBROLIZUMAB AND 5-FU, IN PARTICIPANTS WITH TREATMENT-NAIVE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA |
III |
in corso |
CARCINOMA TESTA E COLLO |
- SC Oncologia Clinica Sperimentale Testa – Collo |
|
A RANDOMIZED, CONTROLLED, MULTI-CENTER TRIAL EVALUATING ZONGERTINIB AS AN ADJUVANT MONOTHERAPY COMPARED WITH STANDARD OF CARE IN PATIENTS WITH EARLY-STAGE, RESECTABLE NON-SMALL CELL LUNG CANCER (STAGE II-IIIB) HARBORING TYROSINE KINASE DOMAIN ACTIVATING HER2 MUTATIONS |
III |
in corso |
CARCINOMA POLMONARE |
- SC Oncologia Clinica Sperimentale Toraco - Polmonare |
|
A PHASE 2 STUDY OF INTRATUMORAL ADMINISTRATION OF L19IL2/L19TNF IN LOCALLY ADVANCED BASAL CELL CARCINOMA PATIENTS PROGRESSED OR INTOLERANT TO SYSTEMIC TREATMENT |
II |
in corso |
CARCINOMA BASALE |
- SC Oncologia Clinica Sperimentale del Melanoma – Immunoterapia e Terapie Innovative |
|
A PHASE 2 CONTROLLED RANDOMIZED STUDY OF THE EFFICACY OF L19IL2 OR L19TNF OR L19IL2/L19TNF INTRALESIONAL INJECTIONS FOR THE TREATMENT OF LOCALLY ADVANCED BASAL CELL CARCINOMA PATIENTS |
II |
in corso |
CARCINOMA BASOCELLULARE |
- SC Oncologia Clinica Sperimentale del Melanoma – Immunoterapia e Terapie Innovative |
|
A PHASE 2 STUDY OF INTRATUMORAL ADMINISTRATION OF L19IL2/L19TNF IN LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA PATIENTS PROGRESSING ON OR INTOLERANT TO SYSTEMIC TREATMENT |
II |
in corso |
CARCINOMA CUTANEO |
- SC Oncologia Clinica Sperimentale del Melanoma – Immunoterapia e Terapie Innovative |
